A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL

This is a Phase 1 study to evaluate FIT-CD19-CAR-T (ARM011) safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.

Trial Details

NCT ID
NCT07066397
Phase
PHASE1
Sponsor
TriArm Therapeutics (Taiwan) Limited
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • ARM011
  • Fludarabine
  • Cyclophosphamide
Locations (sample)
  • Taipei, Taiwan|25.05306,121.52639

Key Eligibility Criteria

  • Male or female subjects age ≥18 years
  • Diagnosis of ALL
  • Refractory to or relapsed after current standard treatment, and not suitable or unable to wait for other treatment options
  • Disease burden: Bone marrow with evidence of disease.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →